CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
about
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaTremelimumab: research and clinical developmentMelanoma: oncogenic drivers and the immune systemImmunotherapy for prostate cancer: recent developments and future challengesModulation of GITR for cancer immunotherapyHomeostasis and function of regulatory T cells (Tregs) in vivo: lessons from TCR-transgenic TregsTherapeutic cancer vaccines: past, present, and futureReview of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experienceImmunotherapy for brain cancer: recent progress and future promiseSuppression, subversion and escape: the role of regulatory T cells in cancer progressionDetection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscopeDistinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cellsSynergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 BlockadeCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyAptamers: A New Technological Platform in Cancer ImmunotherapyCombination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine productionEngulfing tumors with synthetic extracellular matrices for cancer immunotherapyPD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsImmunosuppressive strategies that are mediated by tumor cellsStructural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumabAn old enzyme for current needs: adenosine deaminase and a dendritic cell vaccine for HIV.Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trialCurrent status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.In vivo imaging of T cell delivery to tumors after adoptive transfer therapy.Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE).Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapyAgonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsImmunotherapy in acute leukemiaChemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype.In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulationIntraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinomaTLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo.
P2860
Q24629841-9CD0A48A-583F-458D-AAD5-01E8D95A7C03Q26752822-93866F50-483D-44BC-9FDF-438447A2DC6CQ26775598-5A19A68E-A7CE-4834-881B-DB1A007FF48CQ26852388-44C42925-AE79-4E18-874E-82596D5A3E48Q26853557-C0D48495-2347-4109-B847-C134DDECFB99Q26853599-D40F3251-1FDB-41CC-9B2B-B037067548A0Q26863283-E65EB7C6-E821-4473-952C-320265535737Q26995499-2E0AEA9F-8C3D-4C36-8C6D-AB14B99DE403Q27015881-0011B283-BC3E-45F9-88EA-FD8F5228D4CAQ27026151-E909B0C0-F78C-47B7-9E70-0F2A6706F6CEQ27334728-E0CA1B7B-FDCB-42B5-8EB7-B37DDF9D8EB2Q27438176-DB97EED9-C3D0-4F25-AA3F-4B7E91C55DF6Q27487939-49C442E8-D37E-4BFB-A7A2-781856C570A6Q28066199-18C94C04-2DAC-464B-80B8-855D1291D572Q28068981-39B02E99-6131-4B73-A177-4D0578FC6A78Q28740530-D8DDFCA0-B687-4021-A5B5-8F6749C8F579Q28749647-6178BC2A-F25E-47DB-BA4D-80A38DD0236BQ29619686-4AD0AF3F-CB68-47D5-9529-862669A77D68Q29636247-7E55A520-39E0-426C-8184-B0E8D4AD1E03Q30274619-4C96BB02-D4DB-4E6F-A7BA-DCF978CE0F69Q30407263-FC4F81E2-2471-4D9A-97A4-7C7D26F64642Q30407940-9AAC3634-1247-409A-B770-FA5B1A0D94FCQ30412300-4A3F558A-40BD-4A5E-885C-AE8FC8A7C450Q30479855-02445A92-E38A-490E-818C-09074A2BCFB2Q30525394-ABA1A2D4-291B-4955-A5DA-3E70B1415B8DQ30846001-E3131917-5197-4311-84EC-A226B84B43D9Q31044261-D64CD289-EC99-445F-9D84-473D82011957Q33522281-3DBA5D36-8DC8-4CD5-A4E9-9752BA3372BBQ33573450-5513FFA7-B954-40CA-BB3E-12B6D67EA64CQ33584997-2D266121-E357-4FB1-8DBC-D86DA09DBAC0Q33699687-2D1AF091-06D1-49FA-A491-91A3AAE98AEDQ33707098-B4BAADA3-D048-496E-8A02-5C5912F9B773Q33730129-4E39E722-2C06-4E94-99D7-7EE25B20569AQ33730171-E06686A4-0829-47AA-AAD4-5F6F8C733877Q33731552-C0E2F1A6-A3F9-4B21-A598-42EBA33EF2A9Q33754618-D9D6B165-A40B-4D26-B019-7C7B24AF1AFFQ33837085-F62FA675-4E91-4A91-92D9-0F16C20AF663Q33848077-5B01FD7A-4C37-4E7C-9F5D-EDA1C07F8C25Q33865610-4777E743-04A2-4B1B-ACE7-6C12A777A430Q33886184-C2500EEA-EBB3-4827-A40D-416D21EF2321
P2860
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
CTLA4 blockade and GM-CSF comb ...... fector and regulatory T cells.
@en
type
label
CTLA4 blockade and GM-CSF comb ...... fector and regulatory T cells.
@en
altLabel
CTLA4 blockade and GM-CSF comb ...... ffector and regulatory T cells
@en
prefLabel
CTLA4 blockade and GM-CSF comb ...... fector and regulatory T cells.
@en
P2860
P50
P356
P1476
CTLA4 blockade and GM-CSF comb ...... fector and regulatory T cells.
@en
P2093
Karl S Peggs
P2860
P304
P356
10.1172/JCI27745
P407
P577
2006-06-15T00:00:00Z